Our Vast Clinical Experience

Our innovation stands on a solid foundation of extensive
clinical experience, including our First-in-Human (FIH) clinical
trial in Europe, numerous compassionate use procedures,
and the ongoing Early Feasibility Study (EFS) in the US.

OngoingTrillium™ Early Feasibility Study (EFS)

Prospective, single arm, multi-center, Early Feasibility Study (EFS) to assess the safety and performance of Trillium™
in the treatment of severe or greater tricuspid regurgitation (TR).

Inclusion Criteria:

  • Patient has clinically significant TR graded as severe or greater
  • Peak central venous pressure of ≥ 15mmHg
  • Patient has NYHA functional classification of III or IV
  • Patient is not eligible for standard-of-care surgical or interventional therapy or has refused standard-of-care surgical and interventional therapy or has received standard-of-care TR therapy and remains symptomatic

Exclusion Criteria:

Patients will be excluded from participation if ANY of the
following criteria apply:

  • Severe RV dysfunction defined by TAPSE, RVEF, or RVFAC
  • Non-suitable anatomy according to CT scan
  • Systolic Pulmonary Artery Pressure > 65mmHg
  • Moderate or more mitral valve stenosis
  • Greater than moderate mitral valve regurgitation or aortic valve stenosis/regurgitation
  • Moderate mitral valve regurgitation combined with moderate aortic valve stenosis/regurgitation
  • Kidney dysfunction with estimated Glomerular Filtration Rate (eGFR) < 35 ml/min/1.73 m2 within 60 days prior to the index procedure or patient is on chronic dialysis
  • Liver cirrhosis or moderate or severe liver disease (Child-Turcotte-Pugh class B or C, or a score of 7 or higher)
  • Thrombocytopenia (Platelet count< 100,000/mm3) or thrombocytosis (Platelet count > 750,000/mm3) within 14 days of the index procedure
  • In the opinion of the Investigator or the study eligibility committee, the patient’s life expectancy < 12 months

CompletedTrillium™ First-in-Human (FIH) Study

A prospective, single-arm, multi-center first-in-human (FIH) study to evaluate the safety and performance of
Trillium™. Twenty (20) patients in 9 investigational sites were enrolled. Patient follow-up was set to baseline,
during the procedure, at discharge, after 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, and 3 years
following the index procedure.

OLVZ Aalst
Aalst, Belgium

Antwerp, Belgium

Heart and Diabetes Center NRW
Bad Oeynhausen, Germany

Leipzig Heart Center
Leipzig, Germany

Herzzentrum der Charité (DHZC)
Berlin, Germany

Hospital Alvaro Cunqueiro Hospital
Universitario de Vigo
Vigo, Spain

Hospital Universitario de Salamanca
Salamanca, Spain

Hospital Clinic de Barcelona
Barcelona, Spain


Saving Lives While Gaining Clinical Expertise

Our clinical experience extends beyond clinical trials, with compassionate procedures demonstrating our ability to provide quality care even to patients currently deemed untreatable.

With many successful procedures in Belgium, Spain, Germany, Georgia, and Canada, we have improved patients’ lives while showcasing the capabilities of our entire portfolio: Trillium™, Koala™, and Unica™.

Skip to content